Expiry of Semaglutide's Patent in India
The expiry of semaglutide’s patent in India significantly impacts the country's public health landscape.
Impact on Drug Accessibility and Cost
- GLP-1 receptor agonists, known through brands like Ozempic and Wegovy, are poised to become much more affordable due to generic drug production.
- Up to 50 brands could emerge, potentially reducing costs by one-third to one-fifth.
- This price reduction can notably benefit middle- and lower-income patients grappling with diabetes and obesity.
Benefits of GLP-1 Drugs
- These drugs assist with:
- Regulating Type-2 diabetes.
- Achieving sustained weight loss.
- Lowering cardiovascular risk.
- They offer a comprehensive intervention for metabolic diseases, crucial for an overstretched healthcare system.
Potential Risks and Misuse
- The drugs' efficacy and affordability lead to potential misuse, especially for non-medical or cosmetic purposes.
- Side effects necessitate cautious use, not appropriate for casual consumption.
Regulatory and Scientific Concerns
- Global prescribing thresholds may not suit the Indian context, where metabolic risks occur at lower body weights.
- Unregulated distribution could exacerbate health inequities.
- Monitoring outcomes and adverse effects in Indian populations is vital.
Regulatory Measures and Recommendations
- The Central Drugs Standard Control Organisation (CDSCO) categorizes GLP-1 drugs as Schedule H, requiring a valid prescription.
- India's tendency for over-the-counter drug sales necessitates stricter prescription protocols and robust pharmacovigilance.
- Advertising must focus on the therapy's seriousness rather than portraying it as a quick lifestyle fix.
By balancing affordability with regulatory foresight, India can establish a global benchmark for equitable healthcare.
